Flexion Therapeutics Inc (FLXN) - Financial and Strategic SWOT Analysis Review
![](/report_cover/1896/flexion-therapeutics-inc-flxn-financial-n-strategic-swot-analysis-review_en.gif)
Flexion Therapeutics Inc (FLXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Flexion Therapeutics Inc (Flexion) discovers, develops and commercializes pain therapies. The company's pipeline is focused on indications that include osteoarthritis knee pain, OA pain, disease modification, and acute-post operative pain. The company’s marketed product includes Zilretta which is the first and only extended-release, intra-articular therapy for patients facing with osteoarthritis-related knee pains. Flexion employs its proprietary microsphere technology to combine triamcinolone acetonide (TA) with a polylactic-co-glycolic acid (PLGA) matrix for formulating Zilretta. Its pipeline product candidate FX201 is being developed for treating pain caused from osteoarthritis of the knee and FX301, a NaV1.7 inhibitor in preclinical phase indicated for the treatment of acute-post operative pain. The company markets Zilretta in the US through its own sales and marketing organization and distributors. Flexion is headquartered in Burlington, Massachusetts, the US.
Flexion Therapeutics Inc Key Recent Developments
Oct 12,2021: Pacira to acquire Flexion Therapeutics to boost non-opioid pain portfolio
Oct 01,2021: Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 04,2021: Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
Jul 29,2021: Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021
Jul 12,2021: Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Flexion Therapeutics Inc (Flexion) discovers, develops and commercializes pain therapies. The company's pipeline is focused on indications that include osteoarthritis knee pain, OA pain, disease modification, and acute-post operative pain. The company’s marketed product includes Zilretta which is the first and only extended-release, intra-articular therapy for patients facing with osteoarthritis-related knee pains. Flexion employs its proprietary microsphere technology to combine triamcinolone acetonide (TA) with a polylactic-co-glycolic acid (PLGA) matrix for formulating Zilretta. Its pipeline product candidate FX201 is being developed for treating pain caused from osteoarthritis of the knee and FX301, a NaV1.7 inhibitor in preclinical phase indicated for the treatment of acute-post operative pain. The company markets Zilretta in the US through its own sales and marketing organization and distributors. Flexion is headquartered in Burlington, Massachusetts, the US.
Flexion Therapeutics Inc Key Recent Developments
Oct 12,2021: Pacira to acquire Flexion Therapeutics to boost non-opioid pain portfolio
Oct 01,2021: Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 04,2021: Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
Jul 29,2021: Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021
Jul 12,2021: Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Flexion Therapeutics Inc - Key Facts
Flexion Therapeutics Inc - Key Employees
Flexion Therapeutics Inc - Key Employee Biographies
Flexion Therapeutics Inc - Major Products and Services
Flexion Therapeutics Inc - History
Flexion Therapeutics Inc - Company Statement
Flexion Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Flexion Therapeutics Inc - Business Description
Flexion Therapeutics Inc - Corporate Strategy
Flexion Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Flexion Therapeutics Inc - Strengths
Flexion Therapeutics Inc - Weaknesses
Flexion Therapeutics Inc - Opportunities
Flexion Therapeutics Inc - Threats
Flexion Therapeutics Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Flexion Therapeutics Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Aug 04, 2021: Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
Jul 29, 2021: Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021
Jul 12, 2021: Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors
Jun 14, 2021: Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
Jun 09, 2021: Flexion Therapeutics Announces Appointment of William T. Andrews M.D., F.A.C.P. as Chief Medical Officer
Jun 09, 2021: Flexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical Officer
Jun 02, 2021: Flexion Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
May 13, 2021: Flexion Therapeutics to Present at the RBC Capital Markets 2021 Virtual Global Healthcare Conference
May 12, 2021: Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates
May 05, 2021: Flexion Therapeutics to Report First-Quarter 2021 Financial Results on May 12, 2021
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Flexion Therapeutics Inc - Key Facts
Flexion Therapeutics Inc - Key Employees
Flexion Therapeutics Inc - Key Employee Biographies
Flexion Therapeutics Inc - Major Products and Services
Flexion Therapeutics Inc - History
Flexion Therapeutics Inc - Company Statement
Flexion Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Flexion Therapeutics Inc - Business Description
Flexion Therapeutics Inc - Corporate Strategy
Flexion Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Flexion Therapeutics Inc - Strengths
Flexion Therapeutics Inc - Weaknesses
Flexion Therapeutics Inc - Opportunities
Flexion Therapeutics Inc - Threats
Flexion Therapeutics Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Flexion Therapeutics Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Aug 04, 2021: Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
Jul 29, 2021: Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021
Jul 12, 2021: Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors
Jun 14, 2021: Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
Jun 09, 2021: Flexion Therapeutics Announces Appointment of William T. Andrews M.D., F.A.C.P. as Chief Medical Officer
Jun 09, 2021: Flexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical Officer
Jun 02, 2021: Flexion Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
May 13, 2021: Flexion Therapeutics to Present at the RBC Capital Markets 2021 Virtual Global Healthcare Conference
May 12, 2021: Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates
May 05, 2021: Flexion Therapeutics to Report First-Quarter 2021 Financial Results on May 12, 2021
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Flexion Therapeutics Inc, Key Facts
Flexion Therapeutics Inc, Key Employees
Flexion Therapeutics Inc, Key Employee Biographies
Flexion Therapeutics Inc, Major Products and Services
Flexion Therapeutics Inc, History
Flexion Therapeutics Inc, Subsidiaries
Flexion Therapeutics Inc, Key Competitors
Flexion Therapeutics Inc, Ratios based on current share price
Flexion Therapeutics Inc, Annual Ratios
Flexion Therapeutics Inc, Annual Ratios (Cont...1)
Flexion Therapeutics Inc, Annual Ratios (Cont...2)
Flexion Therapeutics Inc, Interim Ratios
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Flexion Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Flexion Therapeutics Inc, Key Facts
Flexion Therapeutics Inc, Key Employees
Flexion Therapeutics Inc, Key Employee Biographies
Flexion Therapeutics Inc, Major Products and Services
Flexion Therapeutics Inc, History
Flexion Therapeutics Inc, Subsidiaries
Flexion Therapeutics Inc, Key Competitors
Flexion Therapeutics Inc, Ratios based on current share price
Flexion Therapeutics Inc, Annual Ratios
Flexion Therapeutics Inc, Annual Ratios (Cont...1)
Flexion Therapeutics Inc, Annual Ratios (Cont...2)
Flexion Therapeutics Inc, Interim Ratios
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Flexion Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Flexion Therapeutics Inc, Performance Chart (2016 - 2020)
Flexion Therapeutics Inc, Ratio Charts
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Flexion Therapeutics Inc, Performance Chart (2016 - 2020)
Flexion Therapeutics Inc, Ratio Charts
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021